Diagnosis and initial treatment of transplant-eligible high-risk myeloma patients: BSH Good Practice Paper

The British Society for Haematology (BSH) and the UK Myeloma Society have published a comprehensive Good Practice Paper on the diagnosis and initial treatment of transplant-eligible high-risk myeloma patients. Authored by leading experts in the field, this paper provides crucial recommendations based on the latest genetic diagnostics and prospective clinical trial evidence for high-risk myeloma.…

Details

Clinical Service Excellence Programme (CSEP) continues to award excellence in myeloma treatment and care – Summer 2024

Two exceptional hospitals have been awarded the prestigious CSEP accreditation this quarter, and a further five hospitals have successfully reaccredited, highlighting their outstanding contributions to myeloma care.
Explore some of the exceptional achievements and highlights that showcase these hospitals’ commitment to exceptional patient care.

Details

Myeloma UK puts patient involvement first at BSH2024

Myeloma UK once again had a strong presence at the British Society of Haematology (BSH) Annual Conference this year. Held in Liverpool, 28–30 April, both our Health Services Research (HSR) and Clinical Practice Services (CPS) teams showcased their teams work addressing the myeloma patient experience in clinical trials, and how patient and public involvement can positively influence research.

Details